231 related articles for article (PubMed ID: 32239835)
1. [Bullous pemphigoid induced by cancer immunotherapy].
Giroud S; Chiticariu-Durr E
Rev Med Suisse; 2020 Apr; 16(688):624-628. PubMed ID: 32239835
[TBL] [Abstract][Full Text] [Related]
2. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Cosimati A; Rossi L; Didona D; Forcella C; Didona B
J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
[TBL] [Abstract][Full Text] [Related]
3. A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication.
Bezinelli LM; Eduardo FP; Migliorati CA; Ferreira MH; Taranto P; Sales DB; Santi CG; Macarenco RS; Godoy CPV; Corrêa L; Buzaid AC
J Immunother; 2019; 42(9):359-362. PubMed ID: 31246641
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-induced reactivation of bullous pemphigoid.
Kaul S; Wang A; Grushchak S; Albrecht J
Int J Dermatol; 2021 Jun; 60(6):757-758. PubMed ID: 33615441
[No Abstract] [Full Text] [Related]
5. A case of atezolizumab-induced photodistributed bullous pemphigoid.
Leavitt E; Holland V
Dermatol Ther; 2019 Jul; 32(4):e12924. PubMed ID: 30977954
[TBL] [Abstract][Full Text] [Related]
6. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Parakh S; Nguyen R; Opie JM; Andrews MC
Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
[TBL] [Abstract][Full Text] [Related]
8. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
9. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
Zhang X; Sui D; Wang D; Zhang L; Wang R
Front Immunol; 2021; 12():731774. PubMed ID: 34594337
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.
Pop SR; Strock D; Smith RJ
Dermatol Ther; 2022 Aug; 35(8):e15623. PubMed ID: 35669992
[No Abstract] [Full Text] [Related]
11. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.
Hwang SJ; Carlos G; Chou S; Wakade D; Carlino MS; Fernandez-Penas P
Melanoma Res; 2016 Aug; 26(4):413-6. PubMed ID: 27031539
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy (Cemiplimab)-Induced Bullous Pemphigoid: A Possible Pitfall in 18F-FDG PET/CT.
Grünig H; Skawran SM; Nägeli M; Kamarachev J; Huellner MW
Clin Nucl Med; 2022 Feb; 47(2):185-186. PubMed ID: 34507324
[TBL] [Abstract][Full Text] [Related]
13. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
Mazumder A; Darji K; Smith K; Guo M
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593610
[TBL] [Abstract][Full Text] [Related]
14. Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature.
Kosche C; Owen JL; Sadowsky LM; Choi JN
Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735006
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 positive macrophages were increased in a case of pembrolizumab-induced bullous pemphigoid.
Nakai K; Sato Y; Kubo S; Tsuruta D
J Dermatol; 2021 Mar; 48(3):e146-e148. PubMed ID: 33439513
[No Abstract] [Full Text] [Related]
16. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
18. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
Rofe O; Bar-Sela G; Keidar Z; Sezin T; Sadik CD; Bergman R
Clin Exp Dermatol; 2017 Apr; 42(3):309-312. PubMed ID: 28211077
[TBL] [Abstract][Full Text] [Related]
19. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
[TBL] [Abstract][Full Text] [Related]
20. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
Tsiogka A; Bauer JW; Patsatsi A
Acta Derm Venereol; 2021 Jan; 101(1):adv00377. PubMed ID: 33426566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
